AR011231A1 - Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador - Google Patents
Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejoradorInfo
- Publication number
- AR011231A1 AR011231A1 ARP980105979A ARP980105979A AR011231A1 AR 011231 A1 AR011231 A1 AR 011231A1 AR P980105979 A ARP980105979 A AR P980105979A AR P980105979 A ARP980105979 A AR P980105979A AR 011231 A1 AR011231 A1 AR 011231A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- improver
- hyperuricemia
- insulin sensitivity
- administration
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000001431 Hyperuricemia Diseases 0.000 abstract 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 2
- 239000000730 antalgic agent Substances 0.000 abstract 2
- 229960001338 colchicine Drugs 0.000 abstract 2
- 235000005911 diet Nutrition 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 229940116269 uric acid Drugs 0.000 abstract 2
- MJAMNJNCEOHYIU-UHFFFAOYSA-N 1,2-oxazolidine-3,4-dione Chemical class O=C1CONC1=O MJAMNJNCEOHYIU-UHFFFAOYSA-N 0.000 abstract 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- PECKLIXQHBFLKD-UHFFFAOYSA-N 4-amino-5h-1,3-thiazol-2-one Chemical class NC1=NC(=O)SC1 PECKLIXQHBFLKD-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 abstract 1
- 229960003459 allopurinol Drugs 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229960002529 benzbromarone Drugs 0.000 abstract 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- -1 bucoloma Chemical compound 0.000 abstract 1
- 235000019577 caloric intake Nutrition 0.000 abstract 1
- 230000037213 diet Effects 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 229960000905 indomethacin Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000011221 initial treatment Methods 0.000 abstract 1
- LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000194 kebuzone Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000001475 oxazolidinediones Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960003081 probenecid Drugs 0.000 abstract 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960003329 sulfinpyrazone Drugs 0.000 abstract 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 150000001467 thiazolidinediones Chemical class 0.000 abstract 1
- UOJKSDOVAWFEHK-UHFFFAOYSA-N triazol-4-imine Chemical class N=C1C=NN=N1 UOJKSDOVAWFEHK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Biological Depolymerization Polymers (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
El uso de un mejorador de sensibilidad a la insulina que se destina para la fabricacion de un medicamento para el tratamiento o prevencion de lahiperuricemia en un mamífero; y composicion farmacéutica que comprende dicho mejorador. El tratamiento inicial de los síntomas de la hiperuricemia,particularmente la gota, puede ser mediante la administracion de un agente analgésico, tal como colchicina, y/o antiinflamatorio analgésico tal comoindometacina. Es una práctica comun el tratar el problema de plazo más largo de la hiperuricemia mediante el control de la dieta, por ejemplo limitando elconsumo de alcohol o controlando el consumo de calorías. Sin embargo, si este tratamiento dietético no funciona lo suficientemente bien,la enfermedadpuede ser tratada mediante la administracion de fármacos, por ejemplo mediante la adminitracion profiláctica de un agente analgésico, tal como colchicina, opor medio de un estimulador de excrecion de ácido urico, tal como probenecid,sulfinpirazona, cetofenil-butazona, bucoloma o benzbromarona, o un inhibidorde síntesis de ácido urico tal como alopurinol. En particular, los mejoradores de sensibilidad a la insulina empleados se seleccionan preferiblemente delgrupo que consistede compuestos de tiazolidinodiona, compuestos de iminotiazolidinona, compuestos de diiminotiazolidina, compuestos detioxotiazolidinona, compuestos de iminotriazol, compuestos de oxazolidinodiona, compuestos de isoxazolidinodiona y compuestos oxadiazolidinodiona,preferiblemente los compuestos de tiazolidinodiona. Se incluyen también las sales farmacéuticamente aceptables de estos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32318297 | 1997-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011231A1 true AR011231A1 (es) | 2000-08-02 |
Family
ID=18151987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105979A AR011231A1 (es) | 1997-11-25 | 1998-11-25 | Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6353009B1 (es) |
| EP (1) | EP0919232B1 (es) |
| KR (1) | KR19990045531A (es) |
| AR (1) | AR011231A1 (es) |
| AT (1) | ATE278400T1 (es) |
| AU (1) | AU744653B2 (es) |
| BR (1) | BR9805012A (es) |
| CA (1) | CA2254394C (es) |
| CZ (1) | CZ378898A3 (es) |
| DE (2) | DE69826811T4 (es) |
| ES (1) | ES2230657T3 (es) |
| HU (2) | HUP9902721A2 (es) |
| ID (1) | ID21332A (es) |
| IL (1) | IL127219A (es) |
| NO (1) | NO985484L (es) |
| NZ (1) | NZ332895A (es) |
| PL (1) | PL329893A1 (es) |
| RU (1) | RU2190425C2 (es) |
| SA (1) | SA99191266A (es) |
| TR (1) | TR199802441A3 (es) |
| TW (1) | TW592697B (es) |
| ZA (1) | ZA9810788B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE274510T1 (de) | 1998-06-19 | 2004-09-15 | Chiron Corp | Glycogen synthase kinase 3 inhibitoren |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| AU3195700A (en) * | 1999-05-27 | 2000-12-18 | Tanabe Seiyaku Co., Ltd. | Remedies for kidney diseases and method for screening the same |
| US6768008B2 (en) | 2000-04-24 | 2004-07-27 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| US6784199B2 (en) | 2000-09-21 | 2004-08-31 | Aryx Therapeutics | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals |
| US6958355B2 (en) | 2000-04-24 | 2005-10-25 | Aryx Therapeutics, Inc. | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| US7361678B2 (en) * | 2002-03-05 | 2008-04-22 | Transtech Pharma, Inc. | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents |
| RU2230565C1 (ru) * | 2003-03-31 | 2004-06-20 | Савина Лидия Васильевна | Способ снижения уровня мочевой кислоты в организме человека |
| EP1635823A1 (en) * | 2003-05-20 | 2006-03-22 | TransTech Pharma Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| US20050025823A1 (en) * | 2003-07-29 | 2005-02-03 | Fong Andy A.T. | Methods of use of herbal compositions |
| JP2005092923A (ja) * | 2003-09-12 | 2005-04-07 | Renesas Technology Corp | 半導体記憶装置 |
| WO2007018687A1 (en) * | 2005-07-21 | 2007-02-15 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of hyperuricemia related health consequences |
| WO2006012438A2 (en) * | 2004-07-21 | 2006-02-02 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of insulin resistance |
| CA2683089A1 (en) * | 2007-04-05 | 2008-10-23 | Daiichi Sankyo Company, Limited | Benzimidazole derivatives and imidazopyridine derivatives with glucose lowering effect |
| RU2366421C2 (ru) * | 2007-11-01 | 2009-09-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтический состав для лечения диабета |
| AU2010219705A1 (en) | 2009-03-05 | 2011-07-21 | Daiichi Sankyo Company, Limited | Pyridine derivative |
| ES2467923T3 (es) | 2009-09-30 | 2014-06-13 | Transtech Pharma, Llc | Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer |
| US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
| US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
| US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
| US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
| US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
| US8716277B2 (en) * | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
| US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
| US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
| AR089812A1 (es) * | 2012-01-27 | 2014-09-17 | Teijin Pharma Ltd | Agente terapeutico para la diabetes mellitus |
| WO2017176770A1 (en) * | 2016-04-04 | 2017-10-12 | The Schepens Eye Research Institute, Inc. | Peroxisome proliferator-activated receptor gamma selective agonists for inhibition of retinal pigment epithelium degeneration or geographic atrophy |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| JPS58118577A (ja) | 1982-01-07 | 1983-07-14 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
| JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| WO1986007056A1 (en) | 1985-05-21 | 1986-12-04 | Pfizer Inc. | Hypoglycemic thiazolidinediones |
| ZA873745B (en) | 1986-06-04 | 1988-10-26 | Daiichi Seiyaku Co | Benzopyran derivatives |
| US4873255A (en) | 1987-02-04 | 1989-10-10 | Sankyo Company Limited | Thiazolidinone derivatives, their preparation and their use |
| FI91869C (fi) | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
| EP0295828A1 (en) | 1987-06-13 | 1988-12-21 | Beecham Group Plc | Novel compounds |
| US5260445A (en) | 1987-09-04 | 1993-11-09 | Beecham Group P.L.C. | 2,4-thiazolidinediones |
| US5194443A (en) | 1987-09-04 | 1993-03-16 | Beecham Group P.L.C. | Compounds |
| US5232925A (en) | 1987-09-04 | 1993-08-03 | Beecham Group P.L.C. | Compounds |
| DE3856378T2 (de) | 1987-09-04 | 2000-05-11 | Beecham Group P.L.C., Brentford | Substituierte Thiazolidindionderivate |
| US5223522A (en) | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5120754A (en) | 1988-03-08 | 1992-06-09 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5061717A (en) | 1988-03-08 | 1991-10-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| MX15171A (es) | 1988-03-08 | 1993-05-01 | Pfizer | Derivados de tiazolidinodiona hipoglicemicos |
| US5155114A (en) * | 1989-01-23 | 1992-10-13 | Fujisawa Pharmaceutical Company, Ltd. | Method of treatment using pyrazolopyridine compound |
| US4897405A (en) | 1989-04-21 | 1990-01-30 | American Home Products Corporation | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
| GB8919434D0 (en) | 1989-08-25 | 1989-10-11 | Beecham Group Plc | Novel compounds |
| WO1991007107A1 (en) | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
| JPH0469383A (ja) | 1990-07-06 | 1992-03-04 | Yamanouchi Pharmaceut Co Ltd | 置換チアゾリジン誘導体 |
| GB9017218D0 (en) | 1990-08-06 | 1990-09-19 | Beecham Group Plc | Novel compounds |
| WO1994001488A1 (en) * | 1992-07-02 | 1994-01-20 | Novo Nordisk A/S | POLYMERIZATION OF LIGNIN AT ALKALINE pH |
| GB9223059D0 (en) | 1992-11-04 | 1992-12-16 | Bamford Excavators Ltd | Intercooler apparatus |
| JP2845743B2 (ja) | 1992-12-28 | 1999-01-13 | 三菱化学株式会社 | 新規なナフタレン誘導体 |
| JPH06211657A (ja) | 1993-01-21 | 1994-08-02 | Mochida Pharmaceut Co Ltd | 尿酸排泄剤 |
| DK0719140T3 (da) | 1993-09-15 | 2008-03-03 | Daiichi Sankyo Co Ltd | Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM |
| DK0684242T3 (da) | 1993-12-27 | 1999-11-01 | Japan Tobacco Inc | Isoxazolidindionderivat og anvendelse deraf |
| NO305987B1 (no) | 1994-04-11 | 1999-08-30 | Sankyo Co | Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse |
| GB9418958D0 (en) * | 1994-09-21 | 1994-11-09 | Ciba Geigy Ag | Fluorescent whitening agents |
| CA2159938A1 (en) * | 1994-10-07 | 1996-04-08 | Hiroaki Yanagisawa | Oxime derivatives, their preparation and their therapeutic use |
| IL118474A (en) | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
| US5929055A (en) | 1997-06-23 | 1999-07-27 | The Research Foundation Of State University Of New York | Therapeutic method for management of diabetes mellitus |
-
1997
- 1997-03-25 HU HU9902721A patent/HUP9902721A2/hu unknown
-
1998
- 1998-11-18 DE DE69826811T patent/DE69826811T4/de not_active Expired - Lifetime
- 1998-11-18 AT AT98309426T patent/ATE278400T1/de not_active IP Right Cessation
- 1998-11-18 US US09/195,031 patent/US6353009B1/en not_active Expired - Fee Related
- 1998-11-18 DE DE69826811A patent/DE69826811D1/de not_active Expired - Lifetime
- 1998-11-18 ES ES98309426T patent/ES2230657T3/es not_active Expired - Lifetime
- 1998-11-18 EP EP98309426A patent/EP0919232B1/en not_active Expired - Lifetime
- 1998-11-19 NZ NZ332895A patent/NZ332895A/en unknown
- 1998-11-20 CZ CZ983788A patent/CZ378898A3/cs unknown
- 1998-11-23 IL IL12721998A patent/IL127219A/en not_active IP Right Cessation
- 1998-11-24 TW TW087119452A patent/TW592697B/zh not_active IP Right Cessation
- 1998-11-24 CA CA002254394A patent/CA2254394C/en not_active Expired - Fee Related
- 1998-11-24 RU RU98121310/14A patent/RU2190425C2/ru not_active IP Right Cessation
- 1998-11-24 KR KR1019980050484A patent/KR19990045531A/ko not_active Ceased
- 1998-11-24 ID IDP981528A patent/ID21332A/id unknown
- 1998-11-24 BR BR9805012A patent/BR9805012A/pt not_active Application Discontinuation
- 1998-11-24 NO NO985484A patent/NO985484L/no not_active Application Discontinuation
- 1998-11-25 ZA ZA9810788A patent/ZA9810788B/xx unknown
- 1998-11-25 AR ARP980105979A patent/AR011231A1/es unknown
- 1998-11-25 AU AU94102/98A patent/AU744653B2/en not_active Ceased
- 1998-11-25 HU HU9802721A patent/HUP9802721A1/hu unknown
- 1998-11-25 PL PL98329893A patent/PL329893A1/xx unknown
- 1998-11-25 TR TR1998/02441A patent/TR199802441A3/tr unknown
-
1999
- 1999-04-06 SA SA99191266A patent/SA99191266A/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ332895A (en) | 2001-04-27 |
| NO985484D0 (no) | 1998-11-24 |
| AU9410298A (en) | 1999-06-17 |
| RU2190425C2 (ru) | 2002-10-10 |
| DE69826811T2 (de) | 2005-06-16 |
| EP0919232B1 (en) | 2004-10-06 |
| TR199802441A2 (xx) | 1999-10-21 |
| TR199802441A3 (tr) | 1999-10-21 |
| AU744653B2 (en) | 2002-02-28 |
| HUP9802721A1 (hu) | 2000-03-28 |
| CA2254394C (en) | 2009-11-17 |
| KR19990045531A (ko) | 1999-06-25 |
| US6353009B1 (en) | 2002-03-05 |
| DE69826811T4 (de) | 2006-09-21 |
| IL127219A0 (en) | 1999-09-22 |
| SA99191266A (ar) | 2005-12-03 |
| HK1020259A1 (en) | 2000-04-07 |
| ID21332A (id) | 1999-05-27 |
| DE69826811D1 (de) | 2004-11-11 |
| ES2230657T3 (es) | 2005-05-01 |
| ZA9810788B (en) | 1999-05-25 |
| TW592697B (en) | 2004-06-21 |
| CA2254394A1 (en) | 1999-05-25 |
| CZ378898A3 (cs) | 1999-07-14 |
| PL329893A1 (en) | 1999-06-07 |
| IL127219A (en) | 2001-08-08 |
| HU9802721D0 (en) | 1999-01-28 |
| HUP9902721A2 (hu) | 1999-12-28 |
| BR9805012A (pt) | 2000-03-21 |
| EP0919232A1 (en) | 1999-06-02 |
| ATE278400T1 (de) | 2004-10-15 |
| NO985484L (no) | 1999-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR011231A1 (es) | Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador | |
| NO981628D0 (no) | (Metylsulfonyl)fenyl-2-(5H)-furanoner som cox-2 inhibitorer | |
| BR0215240A (pt) | Derivados de calcona e seu uso no tratamento de doenças | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| BR0210267A (pt) | Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases | |
| BRPI0317463B8 (pt) | composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina | |
| CR6210A (es) | Composiciones de celecoxib | |
| CY1107384T1 (el) | Ταχεως διασπειρομενες μορφες δοσομετρησεως ανευ ζελατινης | |
| BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
| HUP0402506A2 (hu) | FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére | |
| BR0009864A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto | |
| TR199902071T2 (xx) | Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m� | |
| BR9809968A (pt) | Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional | |
| IT1245891B (it) | Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali. | |
| YU50401A (sh) | Farmaceutski sastav koji sadrži inhibitore protonske pumpe | |
| BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
| DK599789A (da) | 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler | |
| BR0315662A (pt) | Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona | |
| BR9910678A (pt) | Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto | |
| AR005860A1 (es) | Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización. | |
| NO20025394L (no) | Formuleringer inneholdende et glukokorticoid legemiddel for behandling av bronkopulmon¶re sykdommer | |
| DK0652874T3 (da) | 2-heterocycliske-5-hydroxy-1,3-pyrimidiner der er nyttige som antiinflammatoriske midler | |
| Wang et al. | Evaluation of Anti‐inflammatory and Analgesic Effects of Synthesized Derivatives of Ibuprofen | |
| ATE223376T1 (de) | Bisarylcyclobutenderivate als cyclooxygenasehemmer | |
| BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |